Evidence map›Paper›PMID 37392767›Full record

ArticleJournal of neurosurgery. Case lessons2023

Detailed molecular and pathological analyses of primary intracranial embryonal rhabdomyosarcoma with a BRAF mutation: illustrative case.

Masamichi Abe, Takahiro Ono, Felix Hinz, Masataka Takahashi, Yuko Hiroshima, Koya Kodama, Michihiro Yano, Hiroshi Nanjo, Tsutomu Takahashi, Andreas von Deimling and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurosurgery. Case lessons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Masamichi AbeDepartments of1Neurosurgery and.
Takahiro OnoDepartments of1Neurosurgery and.
Felix Hinz2Department for Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Masataka TakahashiDepartments of1Neurosurgery and.
Yuko Hiroshima4Department of Clinical Pathology, Akita University Hospital, Akita, Japan.
Koya Kodama5Pediatrics, Akita University Graduate School of Medicine, Akita, Japan.
Michihiro Yano5Pediatrics, Akita University Graduate School of Medicine, Akita, Japan.
Hiroshi Nanjo4Department of Clinical Pathology, Akita University Hospital, Akita, Japan.
Tsutomu Takahashi5Pediatrics, Akita University Graduate School of Medicine, Akita, Japan.
Andreas von Deimling2Department for Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Hiroaki ShimizuDepartments of1Neurosurgery and.
Akita University · JPAkita University Hospital · JPHeidelberg University · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe etiological significance of the RAS and PI3K pathways has been reported in systemic embryonal rhabdomyosarcoma (ERMS) but not in primary intracranial ERMS (PIERMS). Herein, the authors present a unique case of PIERMS with a BRAF mutation. OBSERVATIONS: A 12-year-old girl with progressive headache and nausea was diagnosed with a tumor in the right parietal lobe. Semi-emergency surgery revealed an intra-axial lesion that was histopathologically identical to an ERMS. Next-generation sequencing indicated a BRAF mutation as a pathogenic variation, but the RAS and PI3K pathways showed no alteration. Although there is no established reference class for PIERMS, the DNA methylation prediction was closest to that of ERMS, indicating the possibility of PIERMS. The final diagnosis was PIERMS. The patient underwent local radiotherapy (50.4 Gy) and multiagent chemotherapy, with no recurrence for 12 months after surgery. LESSONS: This may be the first case demonstrating the molecular features of PIERMS, especially the intra-axial type. The results showed a mutation in BRAF but not in the RAS and PI3K pathways, which is different from the existing ERMS features. This molecular difference may cause differences in DNA methylation profiles. Accumulation of the molecular features of PIERMS is necessary before any conclusions can be drawn.

Indexed as

BRAFintra-axial tumormethylation profilenext-generation sequencingrhabdomyosarcoma

Identifiers

PMID37392767
PMCPMC10555630
OpenAlexW4382890589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.